We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

GSK plc (GSK) ORD GBP0.3125

Sell:1,672.20p Buy:1,672.80p 0 Change: 4.00p (0.24%)
FTSE 100:0.13%
Market closed Prices as at close on 23 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 4.00p (0.24%)
Market closed Prices as at close on 23 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 4.00p (0.24%)
Market closed Prices as at close on 23 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Contact details

980 Great West Road
United Kingdom
+44 (020) 80475000

Important dates

Future events
Quarterly dividend payment date 11 April 2024 11/04/24
Past events
Quarterly ex-dividend date 22 February 2024 22/02/24
Quarter 4 results 31 January 2024 31/01/24
Final results 31 January 2024 31/01/24
Quarterly dividend payment date 11 January 2024 11/01/24
Quarterly ex-dividend date 16 November 2023 16/11/23
Quarter 3 results 01 November 2023 01/11/23
Quarterly dividend payment date 12 October 2023 12/10/23
Quarterly ex-dividend date 17 August 2023 17/08/23
Quarterly dividend payment date 13 July 2023 13/07/23
Quarterly ex-dividend date 18 May 2023 18/05/23
AGM 03 May 2023 03/05/23
Quarterly results 26 April 2023 26/04/23
Quarterly dividend payment date 13 April 2023 13/04/23
AGM 27 March 2023 27/03/23
Annual report 10 March 2023 10/03/23

General stock information

Market cap:
£67.89 billion
Shares in issue:
4.06 billion
Pharmaceuticals & Biotechnology
London Stock Exchange
Sterling pence
FTSE 100,FTSE 350,FTSE All Share,FTSE techMARK All Share,FTSE 350 Higher Yield

Key personnel

  • Emma Walmsley
    Chief Executive Officer, Executive Director
  • Julie Brown
    Chief Financial Officer, Executive Director
  • David Redfern
    President - Corporate Development
  • Regis Simard
    President - Global Supply Chain
  • Phil Thomson
    President - Global Affairs
  • Deborah Waterhouse
    Chief Executive Officer, ViiV Healthcare and President - GSK Global Health
  • Diana Conrad
    Chief People Officer
  • James Ford
    Senior Vice President, Group General Counsel, Legal and Compliance
  • Sally Jackson
    Senior Vice President - Global Communications and Chief Executive Office
  • Shobie Ramakrishnan
    Chief Digital and Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.